Already a DIA Member? Sign in. Not a member? Join.

Sign in

Forgot User ID? or Forgot Password?

Not a Member?

Create Account and Join

Virtual Event

Oct 06, 2020 10:00 AM - Oct 07, 2020 5:25 PM

(US Eastern Standard Time)

Fort Washington, PA 19034

Biosimilars Conference

Session 2: Biosimilars During a Pandemic

Session Chair(s)

Laura  McKinley, PhD

Laura McKinley, PhD

Director, Global Regulatory Policy and Intelligence

Pfizer Inc, United States

As the world continues to navigate the COVID-19 pandemic what will the impact be to biosimilars? This session will discuss the ways biosimilar stakeholders are adjusting to the COVID-19 pandemic to navigate and execute in the new normal. Panelists will present the regulatory perspectives, customer view, and potential impacts to access and uptake.

Learning Objective : At the conclusion of this session, participants should be able to:
  • Recognize the short and long-term regulatory impacts of COVID-19 on biosimilar development and approvals
  • Discuss the customer perspective of pandemic implications to biosimilar use
  • Debate the short and long-term impacts of COVID-19 on access and uptake

Speaker(s)

Peter P. Stein, MD

Speaker

Peter P. Stein, MD

FDA, United States

Director, Office of New Drugs, CDER

Sean  McGowan, MBA

Speaker

Sean McGowan, MBA

AmerisourceBergen, United States

Senior Director, Biosimilars

Juliana Marguerite Reed, MS

Speaker

Juliana Marguerite Reed, MS

The Biosimilars Forum, United States

Executive Director

Have an account?

Be informed and stay engaged.

Don't miss an opportunity - join our mailing list to stay up to date on DIA insights and events.